{
    "id": "7c48960d-6e45-46c0-a490-78bf8f92d8e7",
    "indications": "phentermine topiramate extended-release capsules indicated combination reduced-calorie diet increased physical activity reduce excess body weight maintain weight reduction long term : adults obesity adults overweight presence least one weight-related comorbid condition limitations effect phentermine topiramate extended-release capsules cardiovascular morbidity mortality established . safety effectiveness phentermine topiramate extended-release capsules combination products intended weight loss , including prescription drugs , over-the-counter drugs , herbal preparations , established . pediatric information approved vivus llc 's qsymia® ( phentermine topiramate ) extended-release capsules . however , due vivus llc 's marketing exclusivity rights , product labeled information .",
    "contraindications": "take orally daily morning . avoid evening prevent insomnia ( 2.2 ) . recommended starting 3.75 mg/23 mg ( phentermine mg/topiramate mg ) daily 14 days ; increase 7.5 mg/46 mg daily ( 2.2 ) . escalate based weight loss adults . full prescribing information details regarding discontinuation escalation ( 2.2 ) . gradually discontinue 15 mg/92 mg prevent possible seizure ( 2.3 ) . exceed 7.5 mg/46 mg patients moderate severe renal impairment patients moderate hepatic impairment ( 2.4 , 2.5 ) .",
    "warningsAndPrecautions": "phentermine topiramate extended-release capsules available follows ( table 15 ) : table 15. phentermine topiramate extended-release capsules presentations strength ( phentermine mg/topiramate mg ) description supplied ndc # 3.75 mg/23 mg extended-release capsules white opaque cap printed wpi , orange opaque body printed 2196 unit bottle ( 30 capsules ) 0480-3297-56 7.5 mg/46 mg extended-release capsules white opaque cap printed wpi , green opaque body printed 2195 unit bottle ( 30 capsules ) 0480-3296-56 11.25 mg/69 mg extended-release capsules light yellow opaque cap printed wpi , white opaque body printed 2299 unit bottle ( 30 capsules ) 0480-2299-56 15 mg/92 mg extended-release capsules white opaque cap printed wpi , dark scarlet opaque body printed 2194 unit bottle ( 30 capsules ) 0480-3295-56 store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . keep container tightly closed protect moisture . keep reach children .",
    "adverseReactions": "phentermine topiramate extended-release capsules contraindicated patients : pregnant [ ( 5.1 ) ( 8.1 ) ] glaucoma [ ( 5.3 ) ] hyperthyroidism taking within 14 days stopping monoamine oxidase inhibitors [ ( 7 ) ] known hypersensitivity phentermine , topiramate excipients phentermine topiramate extended-release capsules , idiosyncrasy sympathomimetic amines [ ( 6.2 ) ] .",
    "ingredients": [
        {
            "name": "PHENTERMINE HYDROCHLORIDE",
            "code": "0K2I505OTV"
        },
        {
            "name": "TOPIRAMATE",
            "code": "0H73WJJ391"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B"
        },
        {
            "name": "ETHYLCELLULOSES",
            "code": "7Z8S9VYZ4B"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "organization": "Teva Pharmaceuticals, Inc.",
    "name": "Phentermine and topiramate",
    "effectiveTime": "20241212",
    "indications_original": "Phentermine and topiramate extended-release capsules are indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:\n                  \n                     Adults with obesity\n                     Adults with overweight in the presence of at least one weight-related comorbid condition\n                  \n                  \n                     Limitations of Use\n                  \n                  \n                     The effect of phentermine and topiramate extended-release capsules on cardiovascular morbidity and mortality has not been established.\n                     The safety and effectiveness of phentermine and topiramate extended-release capsules in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.\n                  \n                  \n                     Pediatric use information is approved for Vivus LLC's Qsymia® (phentermine and topiramate) extended-release capsules. However, due to Vivus LLC's marketing exclusivity rights, this drug product is not labeled with that information.",
    "contraindications_original": "Take orally once daily in morning. Avoid administration in evening to prevent insomnia ( 2.2 ). Recommended starting dosage is 3.75 mg/23 mg (phentermine mg/topiramate mg) daily for 14 days; then increase to 7.5 mg/46 mg daily ( 2.2 ). Escalate dosage based on weight loss in adults. See the Full Prescribing Information for details regarding discontinuation or dosage escalation ( 2.2 ). Gradually discontinue 15 mg/92 mg dosage to prevent possible seizure ( 2.3 ). Do not exceed 7.5 mg/46 mg dosage for patients with moderate or severe renal impairment or patients with moderate hepatic impairment ( 2.4 , 2.5 ).",
    "warningsAndPrecautions_original": "Phentermine and topiramate extended-release capsules are available as follows (see Table 15):\n                  \n                     Table 15. Phentermine and Topiramate Extended-Release Capsules Presentations\n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 Strength\n                                 \n                                 (phentermine mg/topiramate mg)\n                              \n                           \n                           \n                              \n                                 Description\n                              \n                           \n                           \n                              \n                                 How Supplied\n                              \n                           \n                           \n                              \n                                 NDC #\n                              \n                           \n                        \n                        \n                           \n                              3.75 mg/23 mg \n            extended-release capsules\n                           \n                           \n                              White opaque cap printed with WPI, orange opaque body printed with 2196\n                           \n                           \n                              Unit of Use Bottle (30 capsules)\n                           \n                           \n                              0480-3297-56\n                           \n                        \n                        \n                           \n                              7.5 mg/46 mg \n            extended-release capsules\n                           \n                           \n                              White opaque cap printed with WPI, green opaque body printed with 2195\n                           \n                           \n                              Unit of Use Bottle (30 capsules)\n                           \n                           \n                              0480-3296-56\n                           \n                        \n                        \n                           \n                              11.25 mg/69 mg \n            extended-release capsules\n                           \n                           \n                              Light yellow opaque cap printed with WPI, white opaque body printed with 2299\n                           \n                           \n                              Unit of Use Bottle (30 capsules)\n                           \n                           \n                              0480-2299-56\n                           \n                        \n                        \n                           \n                              15 mg/92 mg \n            extended-release capsules\n                           \n                           \n                              White opaque cap printed with WPI, dark scarlet opaque body printed with 2194\n                           \n                           \n                              Unit of Use Bottle (30 capsules)\n                           \n                           \n                              0480-3295-56\n                           \n                        \n                     \n                  \n                  Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Keep container tightly closed and protect from moisture. Keep out of reach of children.",
    "adverseReactions_original": "Phentermine and topiramate extended-release capsules are contraindicated in patients:\n                  \n                     Who are pregnant [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]\n                     \n                     With glaucoma [see Warnings and Precautions (5.3)]\n                     \n                     With hyperthyroidism\n                     Taking or within 14 days of stopping a monoamine oxidase inhibitors [see Drug Interactions (7)]\n                     \n                     With known hypersensitivity to phentermine, topiramate or any of the excipients in phentermine and topiramate extended-release capsules, or idiosyncrasy to the sympathomimetic amines [see Adverse Reactions (6.2)]."
}